Food and snack companies may feel the most pressure as weight-loss drugs become more mainstream and affect consumer behaviors, according to Bank of America. Diabetes drugs that mimic gut hormones such as glucagon-like peptide-1, or GLP-1, have found new audiences in people looking to lose weight. In some instances, people taking these medicines have reported less of a hankering for unhealthy foods or alcohol and other drinks. Analyst Geoff Meacham noted there are many unknowns about what the effect of the drugs on consumer behavior will look like in the long term, but he said the highest risk is to alcohol, snacking and beverage products. Weight-management products such as shakes or frozen meals could also be pressured, Meacham added. On the other hand, he said restaurants will likely feel less affected as the pros of eating out such as convenience, taste and sociability won’t change. CNBC Pro compiled some of the stocks that could be at risk that the firm is watching. All data is from LSEG and current as of Friday morning: — CNBC’s Michael Bloom contributed to this report.